XERIS PHARMACEUTICALS INC's ticker is and the CUSIP is 98422LAA5. A total of 6 filers reported holding XERIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,212 | -10.4% | 11,500,000 | 0.0% | 0.02% | 0.0% |
| Q2 2023 | $12,519 | +32.6% | 11,500,000 | +9.5% | 0.02% | +25.0% |
| Q1 2023 | $9,439 | +8.9% | 10,500,000 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $8,668 | -99.9% | 10,500,000 | 0.0% | 0.01% | -14.3% |
| Q3 2022 | $9,802,000 | +2.9% | 10,500,000 | 0.0% | 0.01% | +7.7% |
| Q2 2022 | $9,526,000 | -21.4% | 10,500,000 | 0.0% | 0.01% | -7.1% |
| Q1 2022 | $12,123,000 | -6.8% | 10,500,000 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $13,013,000 | +4.6% | 10,500,000 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $12,446,000 | -20.7% | 10,500,000 | +5.0% | 0.01% | -22.2% |
| Q2 2021 | $15,687,000 | -12.9% | 10,000,000 | -5.9% | 0.02% | -18.2% |
| Q1 2021 | $18,010,000 | +30.2% | 10,625,000 | +34.9% | 0.02% | +29.4% |
| Q4 2020 | $13,836,000 | +78.2% | 7,875,000 | +96.9% | 0.02% | +54.5% |
| Q3 2020 | $7,763,000 | +124.0% | 4,000,000 | +14.3% | 0.01% | +120.0% |
| Q2 2020 | $3,466,000 | – | 3,500,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sessa Capital IM, L.P. | 7,450,000 | $13,103,000 | 0.84% |
| 683 Capital Management, LLC | 8,100,000 | $14,094,000 | 0.67% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 18,000,000 | $31,658,000 | 0.63% |
| Saltoro Capital, LP | 250,000 | $439,000 | 0.22% |
| UBS OCONNOR LLC | 2,000,000 | $3,461,000,000 | 0.07% |
| LAZARD ASSET MANAGEMENT LLC | 7,875,000 | $13,836,000 | 0.02% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4,000,000 | $6,948,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |